In vitro studies of cross-resistance mutations against two hepatitis C virus serine protease inhibitors, VX-950 and BILN 2061. (Q42994273)

12 November 2017

In vitro studies of cross-resistance mutations against two hepatitis C virus serine protease inhibitors, VX-950 and BILN 2061. (English)

1 reference

12 November 2017

1 reference

1 reference

Chao Lin

1

1 reference

12 November 2017

Cynthia A Gates

2

1 reference

12 November 2017

B Govinda Rao

3

1 reference

12 November 2017

Debra L Brennan

4

1 reference

12 November 2017

John R Fulghum

5

1 reference

12 November 2017

Yu-Ping Luong

6

1 reference

12 November 2017

J Daniel Frantz

7

1 reference

12 November 2017

Kai Lin

8

1 reference

12 November 2017

Sue Ma

9

1 reference

12 November 2017

Yun-Yi Wei

10

1 reference

12 November 2017

Robert B Perni

11

1 reference

12 November 2017

Ann D Kwong

12

1 reference

12 November 2017

language of work or name

English

0 references

publication date

8 August 2005

1 reference

Journal of Biological Chemistry

12 November 2017

8

1 reference

based on heuristic

inferred from page(s)

published in

1 reference

12 November 2017

280

1 reference

12 November 2017

44

1 reference

12 November 2017

36784-36791

1 reference

Epidemiology of hepatitis C: geographic differences and temporal trends

12 November 2017

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M506462200

Recovery, persistence, and sequelae in hepatitis C virus infection: a perspective on long-term outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M506462200

Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M506462200

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M506462200

Diagnosis, management, and treatment of hepatitis C

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M506462200

Proteolytic processing and membrane association of putative nonstructural proteins of hepatitis C virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M506462200

Hepatitis C virus-encoded enzymatic activities and conserved RNA elements in the 3' nontranslated region are essential for virus replication in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M506462200

The hepatitis C virus NS3 serine proteinase and NS4A cofactor: establishment of a cell-free trans-processing assay

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M506462200

Crystal structure of the hepatitis C virus NS3 protease domain complexed with a synthetic NS4A cofactor peptide

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M506462200

Approaching a new era for hepatitis C virus therapy: inhibitors of the NS3-4A serine protease and the NS5B RNA-dependent RNA polymerase.

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M506462200

An NS3 protease inhibitor with antiviral effects in humans infected with hepatitis C virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M506462200

Combination of a hepatitis C virus NS3-NS4A protease inhibitor and alpha interferon synergistically inhibits viral RNA replication and facilitates viral RNA clearance in replicon cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M506462200

In vitro resistance studies of hepatitis C virus serine protease inhibitors, VX-950 and BILN 2061: structural analysis indicates different resistance mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M506462200

Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M506462200

A continuous assay of hepatitis C virus protease based on resonance energy transfer depsipeptide substrates

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M506462200

Mechanistic role of an NS4A peptide cofactor with the truncated NS3 protease of hepatitis C virus: elucidation of the NS4A stimulatory effect via kinetic analysis and inhibitor mapping

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M506462200

Kinetics of the reversible inhibition of enzyme-catalysed reactions by tight-binding inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M506462200

Molecular views of viral polyprotein processing revealed by the crystal structure of the hepatitis C virus bifunctional protease-helicase

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M506462200

Immune evasion by hepatitis C virus NS3/4A protease-mediated cleavage of the Toll-like receptor 3 adaptor protein TRIF

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M506462200

Control of antiviral defenses through hepatitis C virus disruption of retinoic acid-inducible gene-I signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M506462200

Regulation of Interferon Regulatory Factor-3 by the Hepatitis C Virus Serine Protease

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M506462200

Mutations conferring resistance to a potent hepatitis C virus serine protease inhibitor in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M506462200

In Vitro Selection and Characterization of Hepatitis C Virus Serine Protease Variants Resistant to an Active-Site Peptide Inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M506462200

Antiretroviral drug resistance testing in adults infected with human immunodeficiency virus type 1: 2003 recommendations of an International AIDS Society-USA Panel

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M506462200

Prevalence and clinical correlates of YMDD variants during lamivudine therapy for patients with chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M506462200

Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M506462200

Resistance Profile of a Hepatitis C Virus RNA-Dependent RNA Polymerase Benzothiadiazine Inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M506462200

Characterization of resistance to non-obligate chain-terminating ribonucleoside analogs that inhibit hepatitis C virus replication in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M506462200

21 January 2018

Identifiers

DOI

10.1074/JBC.M506462200

1 reference

12 November 2017

1 reference